The pituitary gland, often referred to as the master gland, is responsible for producing a variety of essential hormones that regulate growth, metabolism, and reproductive functions. Because it is composed of different types of specialized cells, it is possible for more than one hormone system to be disrupted simultaneously. Specifically, the co-occurrence of prolactinoma and acromegaly is a recognized clinical phenomenon in endocrinology. This dual presentation usually arises from a single pituitary tumour that possesses the ability to secrete both prolactin and growth hormone. Understanding how these conditions interact is vital for ensuring that patients receive a comprehensive diagnosis and a treatment plan that addresses the full scope of their hormonal imbalance.
What We’ll Discuss in This Article
- The biological mechanisms behind mixed pituitary tumours.
- How growth hormone and prolactin co-secretion impacts the body.
- The prevalence of dual hormone production in acromegaly patients.
- Diagnostic challenges when multiple hormones are elevated.
- UK treatment protocols for managing multi-functioning adenomas.
- The importance of long term monitoring for pituitary health.
The Occurrence of Mixed Pituitary Adenomas
It is indeed possible for a patient to experience symptoms of both prolactinoma and acromegaly at the same time, most commonly due to what is known as a mixed pituitary adenoma. These are single tumours that contain two distinct types of cells: lactotrophs, which produce prolactin, and somatotrophs, which produce growth hormone. In some cases, a single cell type called a mammosomatotroph can produce both hormones simultaneously. Because these cells share a common developmental lineage in the pituitary gland, it is not uncommon for a tumour to involve both types.
Research indicates that approximately 25 percent of patients diagnosed with acromegaly also have elevated prolactin levels due to co-secretion by the same tumour. This mixed secretion can lead to a complex clinical picture where the physical changes of acromegaly, such as enlarged hands and feet, are accompanied by symptoms of hyperprolactinaemia, such as galactorrhoea or menstrual irregularities. While it is rare for a person to have two completely separate tumours in the pituitary gland, the existence of a single tumour producing multiple hormones is a well-documented occurrence in specialist endocrine clinics across the UK. You can find further details on how these growths are managed on the NHS page for pituitary tumours.
Symptoms of Combined Hormone Excess
When prolactinoma and acromegaly occur together, the patient may experience a wide range of symptoms that affect multiple body systems. Acromegaly is primarily characterized by the slow and progressive enlargement of bones and soft tissues. This often manifests as an increase in shoe or ring size, changes in facial features such as a prominent brow or jaw, and thickening of the skin. Patients may also experience joint pain, excessive sweating, and a deepening of the voice. These changes occur because the excess growth hormone stimulates the liver to produce insulin like growth factor 1, which promotes tissue growth throughout the body.
Simultaneously, the excess prolactin can cause specific reproductive and hormonal issues. In women, this often leads to the cessation of periods, infertility, and unexpected breast milk production. In men, high prolactin levels can result in a reduced sex drive, erectile dysfunction, and sometimes enlarged breast tissue. When these symptoms overlap with the physical changes of acromegaly, it can be challenging for both the patient and the doctor to untangle which hormone is responsible for specific complaints. The cumulative effect of these imbalances can also lead to secondary health issues, such as hypertension, sleep apnoea, and an increased risk of type 2 diabetes.
Diagnostic Procedures for Dual Secretion
The diagnosis of a multi-functioning pituitary tumour requires a comprehensive biochemical evaluation. If a doctor suspects acromegaly, the primary test is the measurement of insulin like growth factor 1 in the blood. Because growth hormone levels fluctuate significantly throughout the day, a single GH measurement is often insufficient. A glucose suppression test is usually required, where the patient drinks a sugary solution and their growth hormone levels are monitored to see if they drop as expected. In acromegaly, the levels remain high despite the glucose intake.
In addition to testing for growth hormone, clinicians will routinely check prolactin levels in any patient with a suspected pituitary mass. If both hormones are found to be elevated, it confirms the presence of a co-secreting tumour. Diagnostic imaging, specifically a high resolution MRI of the brain, is used to visualize the size and position of the tumour. This imaging is crucial for determining if the tumour is pressing on nearby structures, such as the optic nerves, which could impair vision. The NHS guidance on acromegaly outlines these diagnostic steps as the standard approach for identifying hormone-secreting growths.
Treatment Protocols in the UK
The management of a pituitary tumour that secretes both growth hormone and prolactin typically involves a multi disciplinary team of endocrinologists and neurosurgeons. The primary goal of treatment is to normalize hormone levels, reduce the size of the tumour, and alleviate any symptoms caused by the mass effect. In most cases involving acromegaly, the first line of treatment is surgery to remove the tumour, usually performed through the nose in a procedure called transsphenoidal surgery. Successful removal can lead to an immediate drop in both growth hormone and prolactin levels.
If surgery is not possible or does not completely normalize the hormones, medication is used as a secondary measure. Dopamine agonists, such as cabergoline, are highly effective at lowering prolactin levels and can also help reduce growth hormone in some mixed tumours. Additionally, somatostatin analogues may be prescribed specifically to target growth hormone production. In cases where neither surgery nor medication provides sufficient control, radiotherapy may be considered to slowly shrink the remaining tumour tissue over time. The choice of treatment is tailored to the individual’s specific hormone levels and the size and location of the tumour.
The Role of Genetic Screening
While most pituitary tumours occur sporadically without a clear cause, in some instances, they can be part of an inherited genetic syndrome. One example is Multiple Endocrine Neoplasia type 1, which can lead to tumours in the pituitary gland, parathyroid glands, and pancreas. Another rare condition is Familial Isolated Pituitary Adenoma, where multiple family members develop pituitary tumours, often at a young age.
When a patient presents with multiple pituitary hormone issues or a mixed tumour, especially if they are young, clinicians may consider genetic testing. Identifying a genetic cause can help in the management of the patient and allow for the screening of family members who may be at risk. Although the majority of cases are not inherited, the possibility of a genetic link is an important consideration in the comprehensive care of patients with complex pituitary disorders.
Conclusion
It is possible and relatively common for multiple pituitary hormone imbalances, such as prolactinoma and acromegaly, to occur simultaneously due to a mixed pituitary adenoma. These cases require careful diagnostic work to ensure both hormones are identified and managed appropriately. Treatment usually involves a combination of surgery and medication to normalize hormone levels and protect surrounding structures. Early detection is key to preventing long term complications such as vision loss or metabolic disease. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Can a prolactinoma turn into acromegaly?
While a tumour does not usually “change” types, it is possible for a mixed tumour to initially only show symptoms of one hormone before the second hormone level rises enough to cause noticeable changes.
Is the surgery for a mixed tumour more dangerous?
The surgical procedure itself is generally the same, but the surgeon must be aware that the tumour is secreting multiple hormones to ensure all relevant tissue is removed.
Will I need to take medication for both conditions?
Not necessarily, as some medications like cabergoline can help lower both prolactin and growth hormone, depending on the specific characteristics of the tumour.
How often do I need blood tests after treatment?
Most patients require lifelong monitoring, initially every few months and then annually once hormone levels have stabilized.
Can acromegaly symptoms be reversed?
Soft tissue swelling often improves after treatment, but changes to the bone structure are usually permanent, making early diagnosis very important.
Does high prolactin always mean I have a prolactinoma?
No, prolactin can be elevated due to stress, certain medications, or even the “stalk effect” where a different type of tumour presses on the pituitary stalk.
Are mixed tumours more likely to come back after surgery?
The risk of recurrence depends more on the size and invasiveness of the original tumour rather than the specific hormones it secretes.
Authority Snapshot (E-E-A-T Block)
This article provides a medically accurate overview of how multiple pituitary disorders can present simultaneously. It has been authored by the medical content team and reviewed by Dr. Rebecca Fernandez to ensure the highest clinical standards. The content is strictly aligned with NHS and NICE guidance for the management of pituitary adenomas and associated hormonal imbalances.
